Advertisement
Advertisement

AXSM

AXSM logo

Axsome Therapeutics, Inc

211.04
USD
Sponsored
-6.95
-3.19%
Aug 03, 15:59 UTC -4
Closed
exchange

Pre-Market

210.85

-0.19
-0.09%

AXSM Earnings Reports

Positive Surprise Ratio

AXSM beat 21 of 42 last estimates.

50%

Next Report

Next Week
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$225.45M
/
-$0.86
Implied change from Q1 26 (Revenue/ EPS)
+17.91%
/
-31.75%
Implied change from Q2 25 (Revenue/ EPS)
+50.26%
/
-11.34%

Axsome Therapeutics, Inc earnings per share and revenue

On May 04, 2026, AXSM reported earnings of -1.26 USD per share (EPS) for Q1 26, missing the estimate of -0.91 USD, resulting in a -37.87% surprise. Revenue reached 191.20 million, compared to an expected 194.03 million, with a -1.46% difference. The market reacted with a +8.31% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 13 analysts forecast an EPS of -0.86 USD, with revenue projected to reach 225.45 million USD, implying an decrease of -31.75% EPS, and increase of 17.91% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Vertex Pharmaceuticals Inc
Report Date
Aug 03, 2026 For Q2 26
Estimate
$4.82
Actual
$4.73
Surprise
-1.95%
logo
BioNTech SE - ADR
Report Date
Aug 04, 2026 For Q2 26
Estimate
-$2.13
Actual
-$2.24
Surprise
-5.08%
logo
Moderna, Inc. Common Stock
Report Date
Jul 31, 2026 For Q2 26
Estimate
-$2.12
Actual
-$1.97
Surprise
+7.28%
logo
Jazz Pharmaceuticals, Inc.
Report Date
Aug 03, 2026 For Q2 26
Estimate
$6.29
Actual
$5.71
Surprise
-9.34%
logo
Krystal Biotech, Inc. Common Stock
Report Date
Aug 03, 2026 For Q2 26
Estimate
$1.68
Actual
$1.79
Surprise
+6.00%
logo
TG Therapeutics, Inc.
Report Date
Aug 03, 2026 For Q2 26
Estimate
$0.33
Actual
$0.05
Surprise
-84.97%
logo
Twist Bioscience Corporation Common Stock
Report Date
Aug 03, 2026 For Q3 26
Estimate
-$0.50
Actual
-$0.56
Surprise
-11.20%
logo
Castle Biosciences, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.41
Actual
-$0.07
Surprise
+83.12%
logo
Anavex Life Sciences
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.06
Surprise
+15.97%
logo
Compugen Ltd
Report Date
Aug 03, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.07
Surprise
+14.22%
FAQ
For Q1 2026, Axsome Therapeutics, Inc reported EPS of -$1.26, missing estimates by -37.87%, and revenue of $191.20M, -1.46% below expectations.
The stock price moved up 8.31%, changed from $206.53 before the earnings release to $223.70 the day after.
The next earning report is scheduled for Aug 10, 2026.
Based on 13 analysts, Axsome Therapeutics, Inc is expected to report EPS of -$0.86 and revenue of $225.45M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement